English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Prenatal diagnosis of genetic disorders has traditionally relied on invasive procedures such as amniocentesis and chorionic villus sampling (CVS). As these procedures carry a small but significant risk of pregnancy loss, a convenient noninvasive prenatal diagnostic has long been sought. Although fetal cells circulating in the maternal blood have been used for prenatal screening, because of their rarity they require ∼104- to 105-fold enrichment to be detectable (1). Recently, extracellular fetal DNA has been detected in maternal circulation, suggesting that maternal blood might be a useful source of material for noninvasive prenatal diagnosis (2)(3).To quantify fetal DNA in maternal circulation, we established a quantitative, homogeneous TaqMan PCR assay based on fluorogenic probes (4). This technique involves continuous monitoring of the progress of amplification and permits target quantification. Such analytical characteristics as precision, sensitivity, and dynamic range were analyzed using human genomic DNA as template. The reproducibility of DNA extraction and PCR amplification was also determined using as target cell-free DNA extracted from pooled plasma. This assay was then tested by determining the genders of adult donors by measuring cell-free DNA in their plasma. Finally, using the male-specific SRY gene as a marker for male fetuses, we successfully determined the gender of all fetuses tested.We collected blood samples from 38 healthy adult volunteers in EDTA. For the fetal DNA study, following approval by the Perinatal Research Committee and the Research Subjects Review Board at the University of Rochester, 30 pregnant patients were enrolled in a prospective trial with masking of those performing all tests. Maternal blood samples were collected before clinically indicated amniocentesis or CVS. Plasma was isolated immediately by centrifugation twice at 1600 g for 10 min, and then stored at −80 °C. Fetal gender was known from the karyotype, which …

Detection and Quantification by Homogeneous PCR of Cell-free Fetal DNA in Maternal Plasma